Remidi

[FOR PE INVESTORS // 7 DAYS // ZERO TARGET INVOLVEMENT]

Validate Your Commercial Assumptions Before Making Bets

Financials reveal the size of the opportunity. Remidi commercial health data shows what is actually achievable.

Access Sample Framework Book a 20-minute call
Factors scored
30
Data sources
20+
Diligence ROI
25X
vs. traditional CDD
Companies benchmarked
800+
Live Assessment Sandbox
SMB Marketing Automation Category Commercial Health Index
Company Target Buyer Overall Position Pricing Buyer Exp Trust
Storelark TARGET Single-location owner 47 73 36 40 38
Vouchly SMB service owner 79 93 84 100 60
Tendly SMB, 20–100 staff 74 100 52 60 75
Perch Multi-location brands 71 93 32 35 90
Convey Local, going upmarket 66 100 28 35 75
Peer average — 72 96 49 58 75

Active underwriting target Click a column header to sort

“The scores [Remidi] got for each company were pretty damn close — [they] got the dogs right and identified where the value is.”

— VC General Partner

The Remidi Difference

Proprietary Benchmarking

Your target asset is objectively scored against a live database of 800+ benchmarked companies across pricing, positioning, and buyer trust.

Rapid Outside-In Buyer Perspective

Remidi delivers an investor-ready Commercial Health Score in 7 days with zero target company involvement required.

Operator-Validated Intelligence

Our algorithms are built, tuned, and validated by seasoned multi-time Operating Partners and CMOs who know exactly what drives multiple expansion.

How we work

Decades of experience, delivered at AI speed.

AI for speed and depth. Expert operator insight and quality.

AI engine · Operator review · Deliverable

Validation pipelineMachine + operator

  1. 01  ·  AI engine

    Deep competitive research at machine speed.

    Reads everything a buyer can see, scores it the same way for every company, and benchmarks it against 800+ companies.

    Benchmark
    800+ companies
    Time
    Hours, not weeks

  2. 02  ·  Operator review

    Judgments from experts that don’t hallucinate.

    Every validation is reviewed before delivery by multi-time Operating Partners and CMOs who’ve run these exact playbooks. They write the recommendations, not the model.

    Reviewed by
    3X Operating Partner
    Unreviewed output
    Never shipped

  3. 03  ·  Deliverable

    Clear conclusions and an execution roadmap.

    Aimed at the multiple expansion you’d otherwise leave for the buyer: IC-ready deck, sized opportunities, a 30-60-90 plan, and the debrief to go with it.

    Format
    Deck + debrief
    Turnaround
    7–10 business days

Life-Cycle ROI

25X

Diligence Arbitrage

Stop funding expensive, dead-end diligence paths. Catch the weak targets early for a fraction of traditional CDD cost.

4X

Exit Predictability

Portfolio assets scoring in Remidi’s top 25% are 4X more likely to achieve market leadership and command premium multiples at exit.

Track Record & Foundation

Founded by an Operating Partner. Built by Michael Himmelfarb (Global GM Nielsen Shopper Panel, 3X Operating Partner, 3X CMO, BlackRock, Lehman Brothers, Wharton/Booth MBA).

Guided by Industry Veterans. Our data models and algorithms are continuously tuned alongside senior operators, growth tech executives, and enterprise AI scientists.

Select Clients

  • Platinum Equity
  • Mercury
  • Edison Partners
  • Serra Ventures

Why the score matters

Market leaders score higher.

The higher a company scores, the more likely it’s a category leader. Category leaders outscore the weakest quarter of their own category 97% of the time — and leadership concentrates at the top of the scale.

Remidi high-scoring companies are 4X more likely to become category leaders. The top third of companies we score hold 56% of all category leaders.

Read the 800-company study →

Category leadership by Commercial Health Scoren = 800+

Share of companies that are category leaders — 2 in 5 in the top third vs. 1 in 7 in the bottom third

Top third by score40%
Bottom third by score14%
Leaders outscore their category’s weakest quarter
97%
High scorers’ odds of leading their category
4X
Category leaders held by the top third
56%

Protect the Downside at Entry. Focus the Hold. Expand the Multiple at Exit.

1.  Validate the Thesis  ·  Entry

Pre-LOI Screening. Grade target companies from the buyer’s perspective in 7 to 14 days.

Peer Benchmarking. Benchmark commercial viability before spending months on heavy diligence.

What’s inside

  • Pre-LOI Screen — score, percentile, risk flags48 hours
  • Diligence Blueprint — full 30+ factor diagnostic, 3–5 competitors, IC deck10 business days

See the full offer →

SMB Marketing Automation Category Commercial Health Index
Company Target Buyer Overall Position Pricing Buyer Exp Trust
Storelark TARGET Single-location owner 4773364038
Vouchly SMB service owner 79938410060
Tendly SMB, 20–100 staff 74100526075
Perch Multi-location brands 7193323590
Convey Local, going upmarket 66100283575
Peer average — 7296495875

“[Remidi] let us use data to rank the whole portfolio and replace month-long analyst work with faster screening.”

— Value Creation Lead, Mid-Market PE

2.  Prioritize Operating Partner Focus  ·  Hold

Fund IV Portfolio Opportunity Analysis Opportunity Map
Portfolio opportunity map Scatter plot of portfolio companies by Remidi Commercial Health Score (x) and revenue growth 2025 to 2026 (y), divided into four quadrants. MULTIPLE EXPANSION OPPORTUNITIES HIGH PERFORMER REVENUE GROWTH OPPORTUNITIES EXECUTION CHECK REMIDI COMMERCIAL HEALTH SCORE → REVENUE GROWTH '25 → '26 ↑ Endorsely — Multiple expansion opportunity Endorsely Medisync — Multiple expansion opportunity Medisync Herdwise — High performer Herdwise FarmGate — High performer FarmGate FieldIQ — Revenue growth opportunity FieldIQ BuildLens — Revenue growth opportunity BuildLens Storelark — Revenue growth opportunity Storelark CropSignal — Revenue growth opportunity CropSignal

Asset Mapping. Plot your entire fund’s financial upside against real-world commercial strength.

Resource Deployment. Deploy operating team resources precisely where execution gaps limit portfolio growth.

What’s inside

  • Portfolio Opportunity Map — every holding, growth vs. commercial healthWhole fund
  • Tracker — quarterly re-scoring, deltas, board-ready updatePer company

See the full offer →

3.  Engineering Multiple Expansion  ·  Exit

Data-Driven VCPs. Replace subjective, gut-feel onboarding assumptions with an empirical 90-day execution framework.

What’s inside

  • 30-60-90 Value Creation Action Plan — sized, ranked, evidenced10 business days
  • Re-score ahead of sale to prove the plan workedOn request

See the full offer →

Showcase.com 30-60-90 Value Creation Action Plan Action Plan
Days 0–30Build Trust

Showcase customer results and social proof to lower buyer risk.

Trust & Credibility

38Peer avg 75

EvidencePeers carry 2,000–4,000 G2 reviews; Storelark shows almost none — despite 25,000+ businesses served.

Days 30–60Focus GTM

Focus on the single-location, multi-crew owner-operator.

Messaging & Positioning

73Peer avg 96

EvidencePerch and Convey are vacating this buyer as they move upmarket — the lane Storelark is best-positioned to own.

Days 60–90Simplify Buying

Strengthen the land-and-expand motion with a trial offer.

Pricing & Buyer Exp.

36 / 40Peer avg 49 / 58

EvidenceVouchly tops the set (79) on exactly this low-friction entry; Convey and Perch stay quote-gated.

How it works

Measuring the view of your customer.

30+ unique factors scored objectively and consistently, not on opinion — from the buyer’s side of the table.

  1. 01

    30+ unique factors

    Scored objectively and consistently, not on opinion.

  2. 02

    Every element of commercial strategy

    Messaging, positioning, pricing, buyer experience, and trust.

  3. 03

    20+ data sources

    Public sources only — the buyer’s perspective of you and your competitors, with no work required from the company.

  4. 04

    GTM experts analyze the results

    And write the recommendations, drawing on decades of operating experience.

Scope

This assessment measures how effectively each company’s commercial strategy is executed through its public-facing digital presence — messaging, pricing transparency, buyer enablement, trust signals, and competitive positioning. It does not assess the underlying strategy itself. A deeper engagement with company participation evaluates strategic fundamentals and quantifies revenue upside.

Calibration

Every score is evidence-based. Scores are calibrated against a growing database of 800+ B2B assessments and expert-reviewed before delivery.

Examples

See what a full commercial strategy assessment looks like.

Every assessment delivers a comprehensive scored report with dimension breakdowns, competitive benchmarks, and prioritized recommendations. Three real examples across very different industries.

HardwareSample report

Janam Technologies

Rugged Mobile Computing · Part of HID (ASSA ABLOY)

12

Early / Rebuilding

Messaging & Positioning12
Pricing & Packaging0
Buyer Experience5
Trust & Credibility22

Product specs dominate without buyer outcomes. No visible social proof. Differentiation claimed but unproven. A strong product with weak commercial execution.

View report →
Marketing ServicesSample report

Boundless Markets

B2B Marketing Research & Intelligence

57

Approaching Ready

Messaging & Positioning100
Pricing & Packaging20
Buyer Experience55
Trust & Credibility68

Messaging scored 100. Strong trust signals when competitive differentiation is included. Gaps in third-party validation and buyer self-service create deal friction.

View report →
Enterprise SaaSSample report

Agiloft

Contract Lifecycle Management · PE-Backed (2024)

65

Approaching Ready

Messaging & Positioning84
Pricing & Packaging25
Buyer Experience30
Trust & Credibility91

Exceptional trust signals (91) with clear, evidenced differentiation. One critical gap: Buyer Experience scores 30 and pricing is invisible. Strong product with a weak evaluation path costing pipeline.

View report →

Research

The Commercial Health Brief.

Data-driven insights on the commercial strategies that separate winners from the field — pricing, positioning, buyer experience, and trust.

All articles →

August 2026 · LinkedIn

Thinking of trusting AI with your commercial strategy? The data says “not so fast”.

Three leading LLMs were asked for competitive strategy recommendations on the same companies. They disagreed 92% of the time and missed basic company facts. AI can do 80% of the ideation work in seconds — the last 20%, the data, validation, and human judgment, is where 100% of the business value lives.

8 min read  ·  AI, Validation, Commercial Strategy

Issue #4 · May 2026

The Dark Funnel: Why Tech Marketing Attribution Fails and What to Do About It

Standard marketing attribution captures only 30% of what drives a B2B purchase. The other 70% — Gartner’s “Dark Funnel” — sits in pricing, positioning, trust, and the rest of commercial strategy.

6 min read  ·  Dark Funnel, Marketing Attribution, Pricing & Packaging

Issue #3 · April 2026

How to Get the Biggest Return from Commercial Strategy Improvements

Your weakest commercial dimension sets your ceiling. Data from 800+ companies shows that improving all four dimensions in parallel produces compounding returns — companies above median on all four win at 48% vs. 5.6% for those clearing none.

7 min read  ·  Multiplier Effect, Balanced Scoring, Value Creation

Reach out to optimize your value creation roadmap

Tell us what you’re evaluating.

A target, a portfolio company, or the whole fund. We’ll come back with how Remidi would approach it — usually the same day.

50%

First engagement

Start with any one deliverable — a Pre-LOI Screen, a Diligence Blueprint, a Portfolio Map, or a 30-60-90 Plan — at half the standard fee. Same scope, same operator review.

Book a 20-minute call info@remidiworks.com

Newsletter

Get the Commercial Health Brief.

Commercial strategy insights, based on real data. Monthly.

InquiryResponse within one business day

By submitting you agree to our Privacy Policy and Terms.